ro7017773
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 24, 2018 (NCT03507569)
Timeline
Indications
Mechanism of action
- GABA receptor alpha-1 subunitPOSITIVE ALLOSTERIC MODULATOR
GABRA1 positive allosteric modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04299464 | Phase 2 | Jun 30, 2020 | Roche |
| NCT03847987 | Phase 1 | Mar 12, 2019 | Roche |
| NCT03774576 | Phase 1 | Dec 17, 2018 | Roche |
| NCT03507569 | Phase 1 | Apr 24, 2018 | Roche |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 4 | 4 | 2 | 2018 |
1 organizations
Page 1 / 1